Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant TherapyBusiness Wire • 08/23/22
Merck and Orna Therapeutics to collaborate in deal entitling Orna to up to $3.5 billion in milestone paymentsMarket Watch • 08/16/22
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority ReviewBusiness Wire • 08/16/22
Merck and Orna Therapeutics Collaborate to Advance Orna's Next Generation of RNA TechnologyBusiness Wire • 08/16/22
Why You Should Sell the Rally and Buy These 7 Goldman Sachs Conviction List Dividend Blue Chips24/7 Wall Street • 08/12/22
10 defensive stocks that can also provide you with growth and dividends over the long termMarket Watch • 08/10/22
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast CancerBusiness Wire • 08/04/22
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular CarcinomaBusiness Wire • 08/03/22
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate CancerBusiness Wire • 08/03/22
Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?The Motley Fool • 08/03/22
These eight health-care stocks can keep you invested in the market with less worryMarket Watch • 08/02/22
My Top 5 Dividend Stocks For The 2nd Half Of 2022 (My First 5 Picks Beat The S&P By 10%)Seeking Alpha • 08/01/22
Looking for a Growth Stock? 3 Reasons Why Merck (MRK) is a Solid ChoiceZacks Investment Research • 08/01/22
7 Warren Buffett Dividend Stocks That Every Total Return Investor Should Own24/7 Wall Street • 08/01/22